Navigation Links
Study Supports Possible Use of Leukine(R) as a Potential Adjuvant Therapy for High-Risk Melanoma Patients
Date:6/5/2008

- Phase II Data Indicate Overall and Disease-Free Survival -

WAYNE, N.J., June 5 /PRNewswire/ -- Results from an adjuvant trial in high-risk melanoma patients demonstrated that a majority of patients treated with Leukine(R) (sargramostim) achieved disease-free and/or overall survival. These findings, which indicate Leukine's potential in this cancer setting, were released at the 44th annual meeting of the American Society of Clinical Oncology (ASCO).

Results from the Phase II study (ASCO abstract #20027) show that 60 percent of the 45 high-risk patients enrolled in the trial experienced disease-free survival and 64 percent of patients achieved overall survival at 21 months.

"Previous findings suggest that sargramostim may be a potential adjuvant therapy for high-risk melanoma patients," said E. George Elias M.D., Ph.D., Director of Maryland Melanoma Center. "The percentage of patients who achieved disease-free and overall survival in this trial provides further evidence that sargramostim may prove to be a viable treatment option for this patient population and that further study in Phase III trials are needed."

In this trial, adjuvant therapy with Leukine and a synergistic cytokine, IL-2, was generally well-tolerated in patients with high-risk melanoma following potentially curative surgery. Each patient received two years of adjuvant therapy: year one with Leukine and IL-2 and year two with only Leukine. Toxicities were mild to moderate and no hospitalizations were required.

"These data, particularly the overall survival rates, are encouraging, even though preliminary, and indicate Leukine's potential as a treatment in this setting," said Paul MacCarthy, M.D., FRCPI, vice president and head of U.S. Medical Affairs for Bayer HealthCare Pharmaceuticals.

Clinical Trial Overview

This Phase II trial was a single-arm, open-labeled study to evaluate the safety, tolerability and treatment efficacy of Leukine and I
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
2. Newly Published Study Shows OPKOs siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye
3. Ion Mobility Diagnostic Test from Quest Diagnostics is First to Provide Direct Physical Measurement of Lipoprotein Particles, Cardiovascular Disease Indicators, Study Finds
4. Wound Management Technologies, Inc. Announces Evidence Based Study
5. CellCyte Genetics Corporation Selects Washington University School of Medicine to Perform Study on CellCytes Glycoprotein Products in Heart Attack Disease Model
6. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
7. Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
8. Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients
9. Study Findings Show Infection Control Intervention Helps Keep Kids in School
10. Final Results of the CellCept(R) Spare the Nephron (STN) Study Show Maintenance Therapy is Associated with Improved Renal Function
11. Study Finds Disparities in Breast Cancer Treatment Even Among Fully-Insured African-American and Caucasian Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014   Mast Therapeutics, Inc. (NYSE ... that Santosh Vetticaden, Chief Medical Officer and Senior ... personal reasons, in mid-September.  Edwin L. Parsley ... Pharmaceuticals, which Mast acquired earlier this year, will ... interim Chief Medical Officer.  Dr. Parsley previously was ...
(Date:8/29/2014)... 29, 2014 Research and Markets ... Cancer Therapeutics Market & Pipeline Insight 2014" report ... developed to prevent and eradicate the prevalence of cancer ... are confined to low specificity, safety and large number ... for a better solution. It has been discovered that ...
(Date:8/29/2014)... 29, 2014  United Therapeutics Corporation (NASDAQ: ... for the District of New Jersey ... case against Sandoz, Inc. regarding United Therapeutics, Remodulin ® ... ruled that U.S. Patent No. 6,765,117 is both valid ... marketing its generic product until the expiration of that ...
Breaking Medicine Technology:Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2District Court Decision Received In Remodulin Patent Case 2
... 19, 2012 /PRNewswire-Asia/ -- China Health Resource, Inc. (OTCBB: ... product line has experienced double digit sales growth in ... is expected to generate an estimated 50 million yuan ... strength of the Company,s core product lines and rapid ...
... --  Terumo Cardiovascular Systems announced today that it has ... distribute the TigerPaw® System II, a left atrial appendage ... TigerPaw System II is indicated for occlusion of the ... other open cardiac procedures.  It is new to the ...
Cached Medicine Technology:China Health Resource Pharmaceutical Grade Gastrodia Product Line Expected to Contribute $8 Million in Revenue to 2011 Year End 2China Health Resource Pharmaceutical Grade Gastrodia Product Line Expected to Contribute $8 Million in Revenue to 2011 Year End 3Terumo Cardiovascular Systems Becomes Exclusive U.S. Distributor for TigerPaw® System II, Left Atrial Appendage Closure Device 2
(Date:8/30/2014)... 2014 United Theological Seminary is pleased to ... the Master of Theological Studies (MTS). , ... designed for students who wish to pursue further academic study ... to serve the Church and community. Previously, students needed to ... can attend classes from any location where there is an ...
(Date:8/30/2014)... Daily Gossip reveals in its recently published review ... created by Sarah Summer, who can perfectly understand what suffering ... new program actually had to deal with this disorder, too. ... to access it, in an all-natural holistic cure program. , ... effective cure for yeast infection. The author of this program ...
(Date:8/30/2014)... 30, 2014 The establishment and ... has been one of the main strategies of ... a positive impact around the world. , Architecturally ... top trained executives and trainers deliver L. Ron ... Vital statistics demonstrate that significant reduction in ...
(Date:8/30/2014)... New York, New York (PRWEB) August 30, 2014 ... and other incretin mimetic claims continue to move forward ... a statement issued by AstraZeneca PLC on July 31, ... have been named in 409 product liability claims that ... cancer. Court documents indicate that many of these claims ...
(Date:8/30/2014)... 30, 2014 Hastings and Hastings, a ... located throughout Arizona is pleased to report having saved ... specific example among many cases where Hastings and Hastings ... to retain a greater portion of their settlement or ... providing a positive solution for Arizona car accident victims ...
Breaking Medicine News(10 mins):Health News:United Theological Seminary Announces First Fully Online Degree 2Health News:Natural Cure for Yeast Infection Review Exposes New Natural Treatment 2Health News:Cradle of Aviation Museum Opens Its Doors to Long Island Scientologists 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 3Health News:Hastings and Hastings Is Pleased To Report Having Saved A Client $67,100 On A Settlement Of $610,000 2
... lags behind in curbing the maternal and infant mortality ... childbirth complications. ,"Maternal health is the foundation ... function organised here Monday on the eve of Safe ... several MPs and Delhi Health Minister Yoganand Shastri, Hota ...
... due at least in part to an attraction between ... stop eating, and a protein more recently// associated with ... not only binds to leptin but its hold impairs ... may help explain why obese people have so much ...
... Sunday saw yet another nationwide polio immunization drive. However, ... upon officers in Western Uttar Pradesh// whose laxity he ... ,Several officers have been punished in this ... officers according to the Health Minister. ...
... revealed that infants of habitually snoring parents are also ... addition researchers have also found that children with atopy ... snoring. ,Sleep-disordered breathing among children had been ... disorders and heart disease. ,When airflow becomes ...
... requiring work permit to be made mandatory for non-European doctors, ... Service// (NHS), has brought about nervousness among the Indian doctors. ... doctors already working there are expected to be affected in ... assignment. With this rule it would become almost impossible for ...
... Jude Children's Research Hospital in Memphis have found that ... in their parents and vice versa.// Their study, which ... a peer-reviewed journal of the American Cancer Society, says ... health related quality of life (HRQL) as their kid. ...
Cached Medicine News:Health News:Maternal Mortality Rate On Rise In India 2Health News:Researchers Identify The Cause To Obesity 2Health News:Researchers Identify The Cause To Obesity 3Health News:Snoring Runs in the Family 2
... Akers, our ultimate goal is to provide ... and immediate treatment. Each year millions of ... die from late detection or undetected disease ... cripple nations., ,By developing, manufacturing and marketing ...
... BD Macro-Vue RPR (Rapid Plasma Reagin) ... Tests are nontreponemal testing procedures for ... in A Manual of Tests for ... manual are the most widely used ...
Rapid Plasma Reagin (RPR) set is a non-treponemal flocculation test that is,used for the qualitative and semi-quantitative determination of reagin,antibodies in serum or plasma from persons with syph...
... assurance reagent in assays detecting IgG and IgM ... IgM), IgG and IgM antibodies to rubella virus ... antibodies to cytomegalovirus (CMV IgG and IgM), and ... types 1 and 2 (HSV-1 IgG, HSV-1 IgM, ...
Medicine Products: